Regenerative Medicine · Business & Investing

Stem Cell Therapy Cost and Legal Status in the US

By Graham Eckert · · 8 min read

Stem Cell Therapy Cost and Legal Status in the US

Two questions usually arrive together: is stem cell therapy legal in the United States, and how much does it cost? The short answers are "some of it, under conditions" and "anywhere from a few thousand dollars for an unproven injection to well over a million for an approved cell therapy." The gap between those two price points says a lot about what is being sold.

This piece takes the legal question first, because it explains the prices. It is general information, not legal or medical advice, and anyone weighing a treatment should go through it with their own doctor.

Legal and routine: approved stem cell medicine

Blood stem cell transplants from bone marrow, mobilized blood or cord blood have been standard care for leukemia, lymphoma and inherited blood disorders for decades, and insurers generally cover them. The FDA has licensed several public cord blood units as "HPC, Cord Blood" products, starting with Hemacord in 2011, and approved Omisirge, an expanded cord blood product, in April 2023. As of September 2026 the agency's list of approved cellular and gene therapy products also includes Lantidra (2023), donor islet cells for a narrow group of adults with type 1 diabetes, and Ryoncil (December 2024), the first approved mesenchymal stromal cell therapy, for a transplant complication in children.

None of these is sold at walk-in clinics. They are given in hospitals and transplant centers for specific diagnoses.

Legal without approval: a narrow exemption

Most of what clinics sell sits outside that list: bone marrow concentrate, fat-derived stromal vascular fraction (SVF), "amniotic" and "umbilical cord" products from donated birth tissue, exosome injections, and platelet-rich plasma (PRP), which contains no stem cells but is often sold in the same package. Whether these can be sold depends on a federal test in 21 CFR Part 1271. A human cell or tissue product can skip premarket approval, as a so-called 361 product, only if it passes all four checks:

  1. Minimal manipulation. It has been processed only lightly, without changing the tissue's basic nature. Breaking fat down to isolate cells, or growing cells in culture, goes beyond this.
  2. Homologous use. It does the same basic job in the recipient that it did in the donor. Amniotic membrane laid over a wound as a cover can pass; the same tissue ground up and injected into a knee to regrow cartilage does not.
  3. Not combined with another article, apart from a few allowed additives such as water or storage agents.
  4. No systemic effect, or else use in the person it came from or a close blood relative.

A product that fails any check is a 351 product, regulated like a drug. It needs an investigational new drug application (IND) to be tested in people and a license to be sold. A separate "same surgical procedure" exception covers tissue removed and put back into the same patient during a single operation, with no more than basic handling.

Clinics argued for years that their products fit one exemption or the other. The FDA gave the industry a grace period after a 2017 policy framework, and it ended on May 31, 2021. Two federal appeals courts have since sided with the agency on fat-derived SVF: the Eleventh Circuit in 2021 and the Ninth Circuit in 2024, both holding that the SVF at issue was a drug that needed approval and did not fit the surgical exception.

Exosomes fit the exemption even less well. They are particles released by cells, and the federal tissue rules exclude "secreted or extracted human products" from the definition of a tissue product altogether. The FDA treats exosome products meant to treat disease as drugs and biological products and has stated that none is approved.

Phrases that mean less than they sound

Tissue businesses must register with the FDA and list their products. The agency's patient information page states that registration, or a listing on ClinicalTrials.gov, does not mean a product is legally marketed. The same page lists conditions, from osteoarthritis and back pain to autism and lung disease, for which none of these products is approved.

Right to Try is not a clinic loophole

The federal Right to Try Act of 2018 lets some patients with life-threatening conditions seek drugs that have completed a phase 1 trial and remain in active development. Most clinic products have never been through a phase 1 trial, so the law does not reach them.

States are moving in different directions

State Year What changed
Utah 2024 Disclosure rules for certain providers who give treatments using placental stem cell products
Florida 2025 Physicians may offer certain stem cell therapies not approved by the FDA for orthopedics, wound care and pain management, with sourcing, consent and advertising disclaimer rules, from July 1, 2025
Montana 2025 Licensed experimental treatment centers may sell treatments that have completed phase 1 testing; the state's rules took effect in July 2026

State laws do not override federal drug law. Legal commentators have described Florida's statute as being in direct conflict with the federal Food, Drug, and Cosmetic Act, and the FDA has said that, as a matter of policy, it does not comment on state legislation. A state law also says nothing about whether a treatment works.

Part 2: What it costs

Published price surveys

Clinic price lists change constantly, and many clinics quote only after a consultation. The most useful numbers come from researchers who gathered prices systematically and published what they found.

Survey Journal and year Setting Reported prices
Simulated patient contacted US clinics; 65 gave prices The Journal of Knee Surgery, 2018 One same-day knee injection Average about 5,160 dollars; quotes from about 1,150 to 12,000 dollars
Review of marketing websites of 40 companies Ophthalmology, 2019 Eye conditions About 4,000 to 10,500 dollars per treatment
Email, phone and web review of 8 Florida clinics Journal of Translational Medicine, 2020 Heart conditions, given by vein About 6,000 to 20,700 dollars

These are reported quotes from specific years, not current prices, and they usually cover a single round. Many clinics recommend repeat rounds.

Why the numbers vary so much

  • Source of cells. A marrow draw or liposuction adds procedure time and staff; a thawed vial of donor product adds a supplier's markup.
  • Route. Infusions into a vein or the spinal fluid are usually priced above joint injections.
  • Packages. Travel, lodging and "booster" doses are often bundled together.
  • No reference price. Without insurer negotiation or an approved label, nothing anchors the number.

What the money buys, in evidence

For the most common clinic offering, knee arthritis, a 2023 trial in Nature Medicine found that marrow, fat and cord tissue cell injections did no better than a steroid shot at one year, and a 2024 systematic review in Osteoarthritis and Cartilage concluded that stem cell injections probably give little to no improvement in pain. Our earlier piece on stem cell injections for knee pain goes through those trials in detail.

What approved cell therapy costs

Manufactured cell therapies that clear FDA review are among the most expensive medicines sold. Trade press reported in 2025 that Ryoncil's list price was about 194,000 dollars per infusion, or roughly 1.55 million dollars for the full eight-infusion course. That price reflects years of controlled trials, manufacturing under drug-grade quality rules and release testing of every batch. A clinic charging a few thousand dollars is not offering a cheaper version of the same thing. It is offering something that has not been through any of those steps.

Who pays

Insurers generally cover approved transplants and cell therapies for their labeled uses and generally do not cover unapproved injections, which they treat as investigational. Clinic patients usually pay out of pocket, sometimes through medical credit cards or financing plans. In legitimate trials, participants usually do not pay for the experimental product; under 21 CFR 312.8 a sponsor needs FDA authorization to charge for one, and it is granted only in limited cases.

Costs that are not on the quote

  • Imaging and lab work before and after.
  • Treating complications. In 2018 the CDC described 12 patients hospitalized with infections after receiving contaminated umbilical cord blood products.
  • Repeat rounds when the first one does not help.
  • Time lost on treatments with proven benefit.

The Federal Trade Commission has acted against deceptive stem cell advertising. In its first such case, filed in 2018 over "amniotic stem cell therapy," it later mailed refunds of nearly 515,000 dollars to about 270 people. Refunds like that are rare, and most money spent at clinics is never recovered.

Questions readers ask

Can a doctor legally give me my own stem cells?

Sometimes. A doctor may return your own lightly processed tissue during the same operation, and approved products can be used under their labels. Processing cells out of fat, growing them in culture or using them for a different job generally makes the product a drug, which requires an IND or an approval.

Is it legal to travel abroad for treatment?

Travel itself is legal, but US protections do not travel with you, and complications usually come home to be treated. Product standards vary widely between countries.

How do I find a trial that does not charge?

Search ClinicalTrials.gov for your condition, then ask the study team about the sponsor, the IND and whether participants pay. Our guide to reading a ClinicalTrials.gov listing explains each field.

Who can confirm whether a product is approved?

The FDA's Office of Communication, Outreach and Development answers questions about approval status at 800-835-4709 or ocod@fda.hhs.gov. Clinicians who field these questions from patients can find a conversation guide on our page about talking with patients about stem cell clinics, and patients can ask their own doctor to read the answer against their diagnosis.

This explainer is general information, not medical advice. Decisions about treatment, donation or trials belong with a clinician who knows your history.

More on this topic